Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 5;8(11):e71482.
doi: 10.1002/hsr2.71482. eCollection 2025 Nov.

Treatment Response of Morphea Patients Referred to a Tertiary Dermatology Hospital: A Three-Year Cohort Study

Nika Kianfar  1   2 , Mahan Babaahmadi  1 , Shayan Dasdar  1   2 , Seyed Mohammad Vahabi  1 , Kimiya Ghiasvand  1 , Zeinab Aryanian  1   2 , Mahshid Sadat Ansari  1   2 , Ifa Etesami  1   2
Affiliations

Treatment Response of Morphea Patients Referred to a Tertiary Dermatology Hospital: A Three-Year Cohort Study

Nika Kianfar et al. Health Sci Rep. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The changes in disease severity from baseline until 6 months after the start of treatment in 31 patients with more than 6 months of follow‐up. Dermal atrophy, Subcutaneous atrophy, Dyspigmentation, and Skin sclerosis are components of LoSDI. Significance level was measured based on Wilcoxon Signed Ranks Test, a non‐parametric test for paired data; *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: LoSAI, Localized Skin Severity Index; LoSDI, Localized Scleroderma Damage Index; LoSCAT, Localized Scleroderma Cutaneous Assessment Tool.
See this image and copyright information in PMC

References

    1. Jerjen R., Nikpour M., Krieg T., Denton C. P., and Saracino A. M., “Systemic Sclerosis in Adults. Part I: Clinical Features and Pathogenesis,” Journal of the American Academy of Dermatology 87, no. 5 (2022): 937–954. - PubMed
    1. Knobler R., Geroldinger‐Simić M., Kreuter A., et al., “Consensus Statement on the Diagnosis and Treatment of Sclerosing Diseases of the Skin, Part 1: Localized Scleroderma, Systemic Sclerosis and Overlap Syndromes,” Journal of the European Academy of Dermatology and Venereology 38, no. 7 (2024): 1251–1280. - PubMed
    1. Arkachaisri T., Vilaiyuk S., Torok K. S., and Medsger T. A., “Development and Initial Validation of the Localized Scleroderma Skin Damage Index and Physician Global Assessment of Disease Damage: A Proof‐Of‐Concept Study,” Rheumatology 49, no. 2 (2009): 373–381. - PMC - PubMed
    1. Zhang F., Li J., Zhao Q., Liu H., and Zhang F., “Study about Evaluation of Efficacy of Methotrexatein Localized Scleroderma Using Ultrasonography,” Skin Research and Technology 29, no. 3 (2023): e13300. - PMC - PubMed
    1. Ronen S., Ramot Y., Zlotogorski A., and Shreberk‐Hassidim R., “Efficacy of Ultraviolet A1 Phototherapy for Inflammatory, Sclerotic and Neoplastic Dermatological Diseases: A 10‐year Tertiary Referral Center Experience,” Photodermatology, Photoimmunology & Photomedicine 39, no. 3 (2023): 256–262. - PubMed

LinkOut - more resources